Immunotherapeutics for Autoimmune Encephalopathies and Dementias

被引:0
|
作者
Andrew McKeon
机构
[1] Mayo Clinic,College of Medicine
来源
关键词
Autoimmune; Autoimmune encephalopathies; Immunotherapeutics; Encephalopathy; Dementia; Paraneoplastic, Immunotherapy; Steroids; Plasma exchange; Intravenous immune globulin; IVIg; Rituximab; Cyclophosphamide; Azathioprine; Mycophenolate mofetil;
D O I
暂无
中图分类号
学科分类号
摘要
The timely implementation of immunotherapy is key to successful treatment of autoimmune encephalopathies or dementias (from here on will be referred to as autoimmune encephalopathies). There are different levels of diagnostic certainty which should guide the immunological treatment of autoimmune encephalopathies. There is a high level of diagnostic certainty for patients who have classic limbic encephalitis and have a neural antibody detected in serum or CSF (such as potassium channel complex antibody). For these patients, initiating high-dose corticosteroids or IVIg is indicated, with plasma exchange, rituximab or cyclophosphamide used as second-line therapy if first-line therapy proves only partially beneficial. There is a lower level of diagnostic certainty in patients with non-limbic atypical phenotypes (though rapidly progressive) when no neural antibody is detected in serum and CSF. A trial of corticosteroids or IVIg (or both sequentially) may be undertaken in these patients, but if no objective improvements occur, further immunotherapy is unlikely to be beneficial. Antiepileptic treatment also plays a critical role in those who have seizures as well as cognitive symptoms. Evaluation for and treatment of any underlying cancer is another component for those patients with a paraneoplastic cause of encephalitis. An individualized maintenance regimen needs to be designed for patients who do improve with immunotherapy. Individual factors that need to be considered when formulating a program of maintenance treatment include disease severity, antibody specificity and proclivity for disease relapse. Azathioprine and mycophenolate mofetil are frequently used for the purpose of remission maintenance, and should permit gradual withdrawal of steroids, IVIg or more toxic immunosuppressants. The duration of maintenance therapy is uncertain, but this author typically recommends 3–5 years of relapse-free maintenance treatment before discontinuing immunotherapy altogether.
引用
收藏
页码:723 / 737
页数:14
相关论文
共 50 条
  • [31] The expanding spectrum of clinically-distinctive, immunotherapy-responsive autoimmune encephalopathies
    Irani, Sarosh R.
    Vincent, Angela
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2012, 70 (04) : 300 - 304
  • [32] Movement Disorders in Children With Anti-NMDAR Encephalitis and Other Autoimmune Encephalopathies
    Mohammad, Shekeeb S.
    Fung, Victor S. C.
    Grattan-Smith, Padraic
    Gill, Deepak
    Pillai, Sekhar
    Ramanathan, Sudarshini
    Brilot, Fabienne
    Dale, Russell C.
    MOVEMENT DISORDERS, 2014, 29 (12) : 1539 - 1542
  • [33] MHC class II allosteric site drugs: New immunotherapeutics for malignant, infections and autoimmune diseases
    Xu, M
    Li, J
    Gulfo, JV
    Von Hofe, E
    Humphreys, RE
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2001, 54 (1-2) : 39 - 44
  • [34] Human and animal spongiform encephalopathies are autoimmune diseases: A novel theory and its supporting evidence
    Zhu, BT
    INTERNATIONAL REVIEW OF NEUROBIOLOGY, VOL 63, 2005, 63 : 155 - 190
  • [35] Enzymes as Immunotherapeutics
    Farhadi, Shaheen A.
    Bracho-Sanchez, Evelyn
    Freeman, Sabrina L.
    Keselowsky, Benjamin G.
    Hudalla, Gregory A.
    BIOCONJUGATE CHEMISTRY, 2018, 29 (03) : 649 - 656
  • [36] Sublingual immunotherapeutics
    Lim, Dae Hyun
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2015, 58 (07): : 655 - 658
  • [37] Risk of Major Types of Dementias Following Hospital-Diagnosed Infections and Autoimmune Diseases
    Janbek, Janet
    Laursen, Thomas Munk
    Frimodt-Moller, Niels
    Magyari, Melinda
    Haas, Juergen G.
    Lathe, Richard
    Waldemar, Gunhild
    JOURNAL OF ALZHEIMERS DISEASE, 2024, 98 (04) : 1503 - 1514
  • [38] Reversible dementias and treatable dementias
    Senties-Madrid, H.
    Estanol-Vidal, B.
    REVISTA DE NEUROLOGIA, 2006, 43 (02) : 101 - 112
  • [39] MicroRNAs as novel immunotherapeutics
    Heimberger, Amy B.
    Gilbert, Mark
    Rao, Ganesh
    Wei, Jun
    ONCOIMMUNOLOGY, 2013, 2 (08)
  • [40] Attenuation of inducible Th2 immunity with autoimmune disease progression: Implications for the rational design of IDDM immunotherapeutics
    Tian, J
    Olcott, A
    Zekzer, D
    Hansen, L
    D'Angelo, I
    Middleton, B
    Chau, C
    Nguyen, Q
    Selahi, S
    Kaufman, D
    DIABETES, 1998, 47 : A209 - A209